ClinicalTrials.gg
CompletedNCT01468077Updated Aug 17, 2015Results posted

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

A Phase 2 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-17.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
79th of 110
47 · median 97
Started
2011
with 13 others
Phase 2
5 of 110
1 open now
Registered
56th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 79th largest by enrollment, is one of 14 that started in 2011, is one of 5 in phase 2, and was the 56th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This multi-center, randomized, parallel-group, active-controlled, open-label study will evaluate the safety and efficacy of a shortened RoActemra/Actemra (tocilizumab) infusion time compared to the normal infusion time. Patients will be randomized to 8 mg/kg RoActemra/Actemra infusion of 31 minutes every 4 weeks or to RoActemra/Actemra 8 mg/kg infusion of 60 minutes every 4 weeks. The anticipated time on study treatment is 24 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, at least 18 years of age, inclusive
  • Diagnosis of rheumatoid arthritis of at least 6 months duration
  • Moderate to severe active rheumatoid arthritis (DAS28 >/=3.2)
  • Patients received at least 1 disease-modifying anti-rheumatic drug (DMARD) and/or 1 or more TNFalfa-inhibitors over a period of at least 8 weeks

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned surgery within 6 months following randomization
  • Rheumatic disease other than rheumatoid arthritis
  • Prior history of or current inflammatory joint disease other than rheumatoid arthritis
  • Functional class IV (ACR criteria)
  • History of severe allergic reaction to human, humanized or murine monoclonal antibodies
  • Known active current or history of recurrent infection (including tuberculosis)
  • Primary or secondary immunodeficiency (history of or currently active)
  • Body weight >150 kg
  • Previous treatment with any cell-depleting therapies
  • Previous treatment with tocilizumab
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Tocilizumab, Normal Administration

    Tocilizumab 8 mg/kg infusion of 60 minutes duration every 4 weeks for 6 infusions (up to 24 weeks)

    Drug: Tocilizumab

  • Experimental
    Tocilizumab, Fast Administration

    Tocilizumab 8 mg/kg infusion of 31 minutes duration every 4 weeks for 6 infusions (up to 24 weeks). The first infusion was 1 hour. If an infusion reaction occurred during any treatment, 1 hour infusions were used for all subsequent infusions

    Drug: Tocilizumab

Interventions

  • 8 mg/kg infusion

    Also known as: RoActemra, Actemra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Any Infusion Reaction

    An infusion reaction was defined as any adverse event (AE) that occurred during the infusion or during the 24 hours following the infusion and deemed possibly or probably related to tocilizumab.

    Time frame: Baseline (Day 1), and Weeks 4, 8, 12, 16, and 20

Secondary outcomes

  1. Percentage of Participants Discontinuing Tocilizumab in Response to an AE or a Serious Adverse Event (SAE)

    All occurrences of participants who received at least 1 infusion of tocilizumab and then stopped tocilizumab infusions due to an AE or SAE were analyzed.

    Time frame: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, and 24

  2. Percentage of Participants Discontinuing Tocilizumab for Other Reasons

    Participants that stopped the administration of tocilizumab and discontinued the study prematurely due to reasons other than an AE or SAE were analyzed.

    Time frame: Baseline and Weeks, 4, 8, 12, 16, 20, and 24

  3. Percentage of Participants With Increased Liver Enzyme Values of Greater Than (>)1.5 Times, or >3 Times, or >5 Times Over the Upper Limit of Normal (ULN) by Visit Among Participants Who Completed All Visits

    Increased liver enzyme values defined as Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) values of \>1.5 times, or \>3 times, or \>5 times over the ULN. Almost none of the participants had increased measurements of AST, thus only values of ALT were presented. None of the participants presented with increased values of ALT above 3 or 5 ULN at any of the visits. ITT Completers is defined as a subset of the participants in the ITT population who completed all study visits.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, and 24

  4. Percentage of Participants With Increased Lipid Values by Visit Among Participants Who Completed All Visits

    Increased levels of high density lipoproteins (HDL) equal to or greater than (≥)1.5 millimoles per liter (mmol/L), and low density lipoproteins (LDL) ≥4.1 mmol/L, and total cholesterol ≥5.1 mmol/L, are defined according to the Adult Treatment Panel III (ATP-III) guidelines.

    Time frame: Screening and Weeks 4, 8, 12, 16, 20, and 24

  5. Percentage of Participants With a Reduction of at Least 1.2 Points in Disease Activity Score Based on 28-Joint Count (DAS28) by Visit Among Participants Who Completed All Visits

    Improvement in Rheumatoid Arthritis (RA) disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response High sensitivity C-Reactive Protein (hsCRP), and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score less than (\<)3.2, and remission was defined as a DAS28 score \<2.6.

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  6. Percentage of Participants Achieving a DAS28 Score Below 3.2 (Low Disease Activity) by Visit Among Participants Who Completed All Visits

    Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  7. Percentage of Participants Achieving a DAS28 Score Below 2.6 (Remission) by Visit Among Participants Who Completed All Visits

    Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  8. DAS28 Score by Visit Among Participants Who Completed All Visits

    Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.

    Time frame: Baseline, Weeks, 4, 8, 12, 16, 20, and 24

  9. Percentage of Participants Achieving American College of Rheumatology 20 Percent (%) Improvement (ACR20 Response) by Visit Among Participants Who Completed All Visits

    ACR20 response is defined as an improvement of ≥20% in swollen joint count (SJC; 66 joints) and tender joint count (TJC; 68 joints) as well as ≥20% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and acute phase reactive factors (Erythrocyte Sedimentation Rate \[ESR\] or C-Reactive Protein \[CRP\]).

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  10. Percentage of Participants Achieving ACR 50% Improvement (ACR50 Response) by Visit Among Participants Who Completed All Visits

    ACR50 response is defined as an improvement of ≥50% in SJC (66 joints) and TJC (68 joints) as well as ≥50% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).

    Time frame: Weeks, 4, 8, 12, 16, 20, and 24

  11. Percentage of Participants Achieving ACR 70% Improvement (ACR70 Response) by Visit, Among Participants Who Completed All Visits

    ACR70 response is defined as an improvement of ≥70% in SJC (66 joints) and TJC (68 joints) as well as ≥70% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  12. Percentage of Participants Achieving ACR 90% Improvement (ACR90 Response) by Visit Among Participants Who Completed All Visits

    ACR90 response is defined as an improvement of ≥90% in SJC (66 joints) and TJC (68 joints) as well as ≥90% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  13. High Sensitivity C-Reactive Protein (hsCRP) Levels by Visit Among Participants Who Completed All Visits

    hsCRP is a marker for inflammation and is measured in milligrams per liter (mg/L). High levels of this protein indicate inflammation in diseases such as RA.

    Time frame: Screening, Baseline, Weeks 4, 8, 12, 16, 20, and 24

  14. Modified Health Assessment Questionnaire (M-HAQ) Score by Visit Among Participants Who Completed All Visits

    M-HAQ is a self-reported, valid assessment of functional disability in RA. Assessment based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Scores range 0 to 3; without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3.

    Time frame: Baseline, Weeks 4, 8, 12, 20, and 24

  15. Percentage of Participants With Improvement of at Least 0.22 Units in M-HAQ Compared to Baseline Per Visit Among Participants Who Completed All Visits

    M-HAQ is a self-reported, valid assessment of functional disability in RA. Assessment based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Scores range 0 to 3; without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3.

    Time frame: Weeks 4, 8. 12, 20, and 24

07

Results

Posted Aug 17, 2015

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Started2225
Completed1822
Not completed43
Withdrew: Adverse event22
Withdrew: Lack of efficacy11
Withdrew: Physician decision10

Outcome measures

PrimaryPercentage of Participants With Any Infusion Reaction

An infusion reaction was defined as any adverse event (AE) that occurred during the infusion or during the 24 hours following the infusion and deemed possibly or probably related to tocilizumab.

Time frame:
Baseline (Day 1), and Weeks 4, 8, 12, 16, and 20
Reported as:
Number · Percentage of Participants
Percentage of Participants With Any Infusion Reaction
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Percentage of Participants With Any Infusion Reaction13.612.0
Statistical analysis
  • Tocilizumab, Normal Administration vs Tocilizumab, Fast Administration · Risk difference (rd): 0.0164 · 95% CI -0.2685 to 0.2988The CI (confidence interval) is calculated by Exact method based on binomial distribution.
SecondaryPercentage of Participants Discontinuing Tocilizumab in Response to an AE or a Serious Adverse Event (SAE)

All occurrences of participants who received at least 1 infusion of tocilizumab and then stopped tocilizumab infusions due to an AE or SAE were analyzed.

Time frame:
Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Tocilizumab in Response to an AE or a Serious Adverse Event (SAE)
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Percentage of Participants Discontinuing Tocilizumab in Response to an AE or a Serious Adverse Event (SAE)9.08.0
SecondaryPercentage of Participants Discontinuing Tocilizumab for Other Reasons

Participants that stopped the administration of tocilizumab and discontinued the study prematurely due to reasons other than an AE or SAE were analyzed.

Time frame:
Baseline and Weeks, 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Tocilizumab for Other Reasons
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Percentage of Participants Discontinuing Tocilizumab for Other Reasons94
SecondaryPercentage of Participants With Increased Liver Enzyme Values of Greater Than (>)1.5 Times, or >3 Times, or >5 Times Over the Upper Limit of Normal (ULN) by Visit Among Participants Who Completed All Visits

Increased liver enzyme values defined as Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) values of \>1.5 times, or \>3 times, or \>5 times over the ULN. Almost none of the participants had increased measurements of AST, thus only values of ALT were presented. None of the participants presented with increased values of ALT above 3 or 5 ULN at any of the visits. ITT Completers is defined as a subset of the participants in the ITT population who completed all study visits.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Increased Liver Enzyme Values of Greater Than (>)1.5 Times, or >3 Times, or >5 Times Over the Upper Limit of Normal (ULN) by Visit Among Participants Who Completed All Visits
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
ALT>1.5 ULN, Week 4125
ALT>1.5 ULN, Week 8610
ALT>1.5 ULN, Week 1265
ALT>1.5 ULN, Week 16610
ALT>1.5 ULN, Week 20125
ALT>1.5 ULN, Week 24245
SecondaryPercentage of Participants With Increased Lipid Values by Visit Among Participants Who Completed All Visits

Increased levels of high density lipoproteins (HDL) equal to or greater than (≥)1.5 millimoles per liter (mmol/L), and low density lipoproteins (LDL) ≥4.1 mmol/L, and total cholesterol ≥5.1 mmol/L, are defined according to the Adult Treatment Panel III (ATP-III) guidelines.

Time frame:
Screening and Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Increased Lipid Values by Visit Among Participants Who Completed All Visits
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
High HDL (≥1.5 mmol/L), Screening4446
High HDL (≥1.5 mmol/L), Week 44455
High HDL (≥1.5 mmol/L), Week 85036
High HDL (≥1.5 mmol/L), Week 123950
High HDL (≥1.5 mmol/L), Week 164441
High HDL (≥1.5 mmol/L), Week 203936
High HDL (≥1.5 mmol/L), Week 244446
High LDL (≥4.1 mmol/L), Screening014
High LDL (≥4.1 mmol/L), Week 41127
High LDL (≥4.1 mmol/L), Week 8632
High LDL (≥4.1 mmol/L), Week 12636
High LDL (≥4.1 mmol/L), Week 16623
High LDL (≥4.1 mmol/L), Week 201132
High LDL (≥4.1 mmol/L), Week 24618
High total cholesterol (≥5.1 mmol/L), Screening3359
High total cholesterol (≥5.1 mmol/L), Week 45673
High total cholesterol (≥5.1 mmol/L), Week 86173
High total cholesterol (≥5.1 mmol/L), Week 125668
High total cholesterol (≥5.1 mmol/L), Week 166164
High total cholesterol (≥5.1 mmol/L), Week 206159
High total cholesterol (≥5.1 mmol/L), Week 245664
SecondaryPercentage of Participants With a Reduction of at Least 1.2 Points in Disease Activity Score Based on 28-Joint Count (DAS28) by Visit Among Participants Who Completed All Visits

Improvement in Rheumatoid Arthritis (RA) disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response High sensitivity C-Reactive Protein (hsCRP), and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score less than (\<)3.2, and remission was defined as a DAS28 score \<2.6.

Time frame:
Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Reduction of at Least 1.2 Points in Disease Activity Score Based on 28-Joint Count (DAS28) by Visit Among Participants Who Completed All Visits
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Week 46755
Week 88973
Week 128982
Week 169477
Week 209482
Week 248986
SecondaryPercentage of Participants Achieving a DAS28 Score Below 3.2 (Low Disease Activity) by Visit Among Participants Who Completed All Visits

Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.

Time frame:
Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving a DAS28 Score Below 3.2 (Low Disease Activity) by Visit Among Participants Who Completed All Visits
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Week 44427
Week 86755
Week 127882
Week 169468
Week 208973
Week 248377
SecondaryPercentage of Participants Achieving a DAS28 Score Below 2.6 (Remission) by Visit Among Participants Who Completed All Visits

Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.

Time frame:
Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving a DAS28 Score Below 2.6 (Remission) by Visit Among Participants Who Completed All Visits
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Week 4229
Week 82836
Week 125073
Week 167846
Week 207259
Week 246155
SecondaryDAS28 Score by Visit Among Participants Who Completed All Visits

Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.

Time frame:
Baseline, Weeks, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · scores on a scale
DAS28 Score by Visit Among Participants Who Completed All Visits
scores on a scaleTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Baseline (n=18,21)5.0 ± 1.15.0 ± 0.9
Week 4 (n=18,21)3.3 ± 0.83.6 ± 1.0
Week 8 (n=18,22)2.9 ± 0.83.1 ± 1.2
Week 12 (n=18,22)2.6 ± 0.92.4 ± 1.0
Week 16 (n=18,21)2.3 ± 0.42.6 ± 1.0
Week 20 (n=18,22)2.3 ± 0.62.6 ± 0.9
Week 24 (n=18,22)2.3 ± 0.62.5 ± 1.0
SecondaryPercentage of Participants Achieving American College of Rheumatology 20 Percent (%) Improvement (ACR20 Response) by Visit Among Participants Who Completed All Visits

ACR20 response is defined as an improvement of ≥20% in swollen joint count (SJC; 66 joints) and tender joint count (TJC; 68 joints) as well as ≥20% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and acute phase reactive factors (Erythrocyte Sedimentation Rate \[ESR\] or C-Reactive Protein \[CRP\]).

Time frame:
Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving American College of Rheumatology 20 Percent (%) Improvement (ACR20 Response) by Visit Among Participants Who Completed All Visits
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Week 45041
Week 86759
Week 127268
Week 168377
Week 208373
Week 248991
SecondaryPercentage of Participants Achieving ACR 50% Improvement (ACR50 Response) by Visit Among Participants Who Completed All Visits

ACR50 response is defined as an improvement of ≥50% in SJC (66 joints) and TJC (68 joints) as well as ≥50% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).

Time frame:
Weeks, 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ACR 50% Improvement (ACR50 Response) by Visit Among Participants Who Completed All Visits
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Week 42818
Week 82836
Week 125050
Week 164446
Week 206755
Week 247273
SecondaryPercentage of Participants Achieving ACR 70% Improvement (ACR70 Response) by Visit, Among Participants Who Completed All Visits

ACR70 response is defined as an improvement of ≥70% in SJC (66 joints) and TJC (68 joints) as well as ≥70% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ACR 70% Improvement (ACR70 Response) by Visit, Among Participants Who Completed All Visits
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Week 4115
Week 81723
Week 122236
Week 161127
Week 202218
Week 242236
SecondaryPercentage of Participants Achieving ACR 90% Improvement (ACR90 Response) by Visit Among Participants Who Completed All Visits

ACR90 response is defined as an improvement of ≥90% in SJC (66 joints) and TJC (68 joints) as well as ≥90% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).

Time frame:
Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ACR 90% Improvement (ACR90 Response) by Visit Among Participants Who Completed All Visits
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Week 400
Week 809
Week 12014
Week 1600
Week 2065
Week 2469
SecondaryHigh Sensitivity C-Reactive Protein (hsCRP) Levels by Visit Among Participants Who Completed All Visits

hsCRP is a marker for inflammation and is measured in milligrams per liter (mg/L). High levels of this protein indicate inflammation in diseases such as RA.

Time frame:
Screening, Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · mg/L
High Sensitivity C-Reactive Protein (hsCRP) Levels by Visit Among Participants Who Completed All Visits
mg/LTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Screening22.8 ± 19.825.9 ± 36.0
Baseline23.5 ± 22.727.0 ± 32.1
Week 44.7 ± 6.63.1 ± 3.4
Week 83.3 ± 3.34.5 ± 3.8
Week 123.2 ± 3.42.6 ± 3.3
Week 162.8 ± 3.13.1 ± 3.3
Week 202.9 ± 3.03.0 ± 3.2
Week 243.2 ± 3.53.4 ± 3.6
SecondaryModified Health Assessment Questionnaire (M-HAQ) Score by Visit Among Participants Who Completed All Visits

M-HAQ is a self-reported, valid assessment of functional disability in RA. Assessment based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Scores range 0 to 3; without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3.

Time frame:
Baseline, Weeks 4, 8, 12, 20, and 24
Reported as:
Mean · scores on a scale
Modified Health Assessment Questionnaire (M-HAQ) Score by Visit Among Participants Who Completed All Visits
scores on a scaleTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Baseline1.29 ± 0.711.50 ± 0.74
Week 40.97 ± 0.641.10 ± 0.64
Week 80.79 ± 0.670.95 ± 0.68
Week 120.80 ± 0.700.98 ± 0.62
Week 160.82 ± 0.690.94 ± 0.69
Week 200.75 ± 0.611.05 ± 0.77
Week 240.68 ± 0.631.07 ± 0.82
SecondaryPercentage of Participants With Improvement of at Least 0.22 Units in M-HAQ Compared to Baseline Per Visit Among Participants Who Completed All Visits

M-HAQ is a self-reported, valid assessment of functional disability in RA. Assessment based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Scores range 0 to 3; without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3.

Time frame:
Weeks 4, 8. 12, 20, and 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Improvement of at Least 0.22 Units in M-HAQ Compared to Baseline Per Visit Among Participants Who Completed All Visits
Percentage of ParticipantsTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Week 444.445.5
Week 872.259.1
Week 1272.254.5
Week 1677.863.6
Week 2066.759.1
Week 2472.250.0

Adverse events

Collected over Screening through Week 24 (or early withdrawal). For early withdrawal two follow-up visits occurred; at 4 weeks and at 12 weeks after the last infusion. A telephone call was sufficient for the last visit if laboratory procedures were not needed.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab, Normal Administration—2/22 (9.1%)20/22 (90.9%)
Tocilizumab, Fast Administration—0/25 (0%)17/25 (68%)
Most frequent serious events
Most frequent serious events
EventTocilizumab, Normal AdministrationTocilizumab, Fast Administration
Infective tenosynovitisInfections and infestations1/220/25
Lymphoma cutisNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/220/25
Most frequent other events
Showing 10 of 51
Most frequent other events
EventTocilizumab, Normal AdministrationTocilizumab, Fast Administration
NasopharyngitisInfections and infestations3/225/25
NeutropeniaBlood and lymphatic system disorders1/224/25
RhinitisInfections and infestations3/220/25
Abdominal pain upperGastrointestinal disorders0/223/25
FatigueGeneral disorders2/223/25
HeadacheNervous system disorders1/223/25
HypercholesterolaemiaMetabolism and nutrition disorders2/223/25
ArthralgiaMusculoskeletal and connective tissue disorders2/221/25
CoughRespiratory, thoracic and mediastinal disorders2/220/25
Urinary tract infectionInfections and infestations0/222/25

Baseline characteristics

Intent-to-treat (ITT) Population: All participants enrolled in the study who had been randomly assigned to one of the two study treatments.

Age, Continuous
Age, Continuous(years)Tocilizumab, Normal AdministrationTocilizumab, Fast AdministrationTotal
Mean57.5 ± 11.859.8 ± 13.158.7 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab, Normal AdministrationTocilizumab, Fast AdministrationTotal
Female172037
Male5510
08

Study locations

8 sites
  • Alborg, 9000, Denmark
  • Frederiksberg, 2000, Denmark
  • Hellerup, 2900, Denmark
  • Holbæk, 4300, Denmark
  • Odense, 5000, Denmark
  • Silkeborg, 8600, Denmark
  • Svendborg, 5700, Denmark
  • Reykjavik, 108, Iceland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2011
First posted
Nov 9, 2011
Start
Nov 2011
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results first posted
Aug 17, 2015
Last update
Aug 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01468077
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 9, 2011
Start date
Nov 2011
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Aug 17, 2015
Last update
Aug 17, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion